Nabriva Publishes Clinical Data Analysis Highlighting Benefits of Outpatient Management of Community Acquired Bacterial Pneumonia (CABP) with Oral XENLETA® (lefamulin) Nabriva Therapeutics US, Inc -Post Hoc analysis published in The Journal of Emergency Medicine demonstrates patients with moderate to severe CABP can be managed effectively as outpatients with a 5-day, monotherapy regimen of oral XENLETA DUBLIN, Ireland, March 16, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that The Journal of Emergency Medicine has published results from a post-hoc analysis of clinical data from the pivotal Lefamulin Evaluation Against Pneumonia (LEAP) 2 Phase 3 clinical trial. Avoiding hospitalization, with an outpatient 5-day regimen of oral XENLETA, as an alternative to the fluoroquinolone, moxifloxacin, was demonstrated in patients with moderate to severe community-acquired bacterial pneumonia (CABP), including those aged 65 years or older with comorbidities. The U.S. Food and Drug Administration (FDA) approved XENLETA for the treatment of adults with CABP in August 2019. XENLETA is the first IV and oral antibiotic with a novel mechanism of action approved by the FDA in nearly two decades.